NASDAQ:QTRXQuanterix Stock Price, Forecast & News

$27.88

+0.08 (+0.29 %)

(As of 07/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$27.39

Now: $27.88▼

$28.30

50-Day Range

$24.05

MA: $26.23▼

$27.94

52-Week Range

$10.90

Now: $27.88▼

$33.67

Volume144,958 shs

Average Volume193,325 shs

Market Capitalization$789.28 million

P/E RatioN/A

Dividend YieldN/A

Beta1.77

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Quanterix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.50, Quanterix has a potential upside of 20.2% from its current price of $27.88.
Amount of Analyst Coverage
Quanterix has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
Quanterix has received 235 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quanterix has received 288 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quanterix has received 55.07% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote “Outperform” if you believe QTRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quanterix does not currently pay a dividend.
Dividend Growth
Quanterix does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quanterix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,237,949.00 in company stock.
Percentage Held by Insiders
Only 25.40% of the stock of Quanterix is held by insiders.
Percentage Held by Institutions
69.28% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Quanterix are expected to grow in the coming year, from ($1.67) to ($1.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quanterix is -17.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quanterix is -17.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quanterix has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.27 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QTRX

Previous Symbol

CUSIPN/A

CIK1503274

Webwww.quanterix.com

Phone617-301-9400

Debt

Debt-to-Equity Ratio0.06

Current Ratio6.80

Quick Ratio6.17

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$56.73 million

Price / Sales13.91

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.59 per share

Price / Book6.07

Profitability

EPS (Most Recent Fiscal Year)($1.63)

Net Income$-40,800,000.00

Net Margins-70.51%

Return on Equity-36.97%

Return on Assets-27.12%

Miscellaneous

Employees177

Outstanding Shares28,310,000

Market Cap$789.28 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

Quanterix (NASDAQ:QTRX) Frequently Asked Questions

How has Quanterix's stock been impacted by COVID-19 (Coronavirus)?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 50.6% and is now trading at $27.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quanterix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Quanterix.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Quanterix.

How were Quanterix's earnings last quarter?

Quanterix Corp (NASDAQ:QTRX) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.03. The company earned $15.73 million during the quarter, compared to the consensus estimate of $12.70 million. Quanterix had a negative net margin of 70.51% and a negative return on equity of 36.97%. View Quanterix's earnings history.

What price target have analysts set for QTRX?

2 Wall Street analysts have issued 12-month price objectives for Quanterix's stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Quanterix's stock price to reach $33.50 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View analysts' price targets for Quanterix.

Has Quanterix been receiving favorable news coverage?

News stories about QTRX stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Quanterix earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news about Quanterix.

Are investors shorting Quanterix?

Quanterix saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,060,000 shares, a decrease of 6.2% from the May 31st total of 1,130,000 shares. Based on an average daily volume of 186,500 shares, the short-interest ratio is presently 5.7 days. Approximately 5.5% of the shares of the company are short sold. View Quanterix's Current Options Chain.

Who are some of Quanterix's key competitors?

Some companies that are related to Quanterix include Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID). View all competitors.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Akoustis Technologies (AKTS), Spero Therapeutics (SPRO), Cloudera (CLDR), Crispr Therapeutics (CRSP), Walt Disney (DIS), InVitae (NVTA), Intellia Therapeutics (NTLA), Veracyte (VCYT) and Allena Pharmaceuticals (ALNA).

Who are Quanterix's key executives?

Quanterix's management team includes the following people:

Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
Mr. Amol Chaubal, Chief Financial Officer (Age 43)
Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $27.88.

How big of a company is Quanterix?

Quanterix has a market capitalization of $789.28 million and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 177 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings